New Challenge to Thai Drug Licensing (Thailand)
This article was originally published in PharmAsia News
Executive Summary
Emcure Pharmaceuticals is being threatened with legal action by the Sanofi-Aventis, patent holder of the cardiac drug Plavix. Emcure secured an order from the Thai government to produce clopidogrel, the generic version of Plavix. In a notice to Bioscience Co. Ltd, the agent of Emcure in Thailand, Sanofi-Aventis said that any unauthorized importation, manufacture, and sale of the generic clopidogrel will infringe Sanofi's patent rights of clopidogrel under Thai law. Sanofi says that in the event of infringement of its patent, the company "will be entitled to sue the company in a civil action for compensation. Emcure says it has received assurances of support from the Thai government. (Click here for more